Get the Stockscreener App
9.41
13.51%
1.12
After Hours:
9.59
0.18
+1.91%
Jade Biosciences Inc stock is traded at $9.41, with a volume of 885.86K.
It is up +13.51% in the last 24 hours and up +28.11% over the past month.
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
See More
Previous Close:
$8.29
Open:
$8.23
24h Volume:
885.86K
Relative Volume:
5.62
Market Cap:
$227.59M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+33.85%
1M Performance:
+28.11%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.925
$9.51
1-Week Range:
$6.565
$9.51
52-Week Range:
$6.565
$13.47
Jade Biosciences Inc Stock (JBIO) Company Profile
Name
Jade Biosciences Inc
Sector
Industry
Phone
617-443-2400
Address
930 WINTER STREET, WALTHAM
Compare JBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
9.41 | 227.59M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Upgrade | Guggenheim | Neutral → Buy |
| May-07-25 | Initiated | Wedbush | Outperform |
| May-05-25 | Initiated | Stifel | Buy |
| May-02-25 | Initiated | TD Cowen | Buy |
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Jade Biosciences Inc Stock (JBIO) Latest News
Guggenheim Upgrades Jade Biosciences to Buy From Neutral, Price Target is $14 - marketscreener.com
Guggenheim upgrades Jade Biosciences stock rating to Buy on transformation - Investing.com Canada
JADE-101 ameliorates IgA nephropathy features in preclinical setting - BioWorld MedTech
Jade Biosciences Presents JADE101 Preclinical Data at the - GlobeNewswire
New IgA Nephropathy Drug Shows 750x Better Binding: JADE101 Outperforms Competitors in Key Metrics - Stock Titan
Jade Biosciences Announces Presentation of Preclinical Data on JADE101 at 62nd European Renal Association Congress - Nasdaq
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress - GlobeNewswire
Breakthrough IgA Nephropathy Treatment: Jade Biosciences Reveals New JADE101 Antibody Data at ERA Congress - Stock Titan
Insider Buying: CEO Tom Frohlich Acquires Shares in Jade Bioscie - GuruFocus
JBIOJade Biosciences Inc Latest Stock News & Market Updates - Stock Titan
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jade Biosciences, Inc. Completes Reverse Merger, Launches Nasdaq Trading as JBIO, and Secures $300 Million Financing - Nasdaq
Jade Biosciences Secures Massive $300M Funding After Nasdaq Debut, First Clinical Trial Set for 2025 - Stock Titan
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target - marketscreener.com
Stifel initiates Jade Biosciences stock with a Buy, $19 target - Investing.com
Stifel initiates Jade Biosciences stock with a Buy, $19 target By Investing.com - Investing.com India
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - marketscreener.com
Aerovate Therapeutics, Inc. Announces Board Changes - marketscreener.com
TD Cowen starts Jade Biosciences coverage with Buy rating By Investing.com - Investing.com Nigeria
TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating - marketscreener.com
TD Cowen starts Jade Biosciences coverage with Buy rating - Investing.com
Aerovate Therapeutics Completes Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Announces Range of Expected Cash Dividend - marketscreener.com
RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics - QuotedData
JBIO Stock Price and Chart — NASDAQ:JBIO - TradingView
Jade Biosciences Highlights JADE-001 Progress in Presentation - TipRanks
Jade Biosciences closes merger with Aerovate Therapeutics - Business in Vancouver
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously ... - Bluefield Daily Telegraph
Jade Biosciences Completes Closing of Merger with Aerovate - GlobeNewswire
Aerovate Therapeutics, Inc. SEC 10-Q Report - TradingView
Aerovate Therapeutics (AVTE) Declares Special Dividend Amid Merg - GuruFocus
Aerovate Therapeutics stockholders approve proposed merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related Proposals - marketscreener.com
Aerovate approves reverse split ahead of Jade merger - Investing.com
Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - The Malaysian Reserve
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - PR Newswire
Aerovate Therapeutics Inc. (AVTE) reports earnings - qz.com
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc.AVTE - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE, BMTX, PFIE, ALTR on Behalf of Shareholders - ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AVTE, BLUE on Behalf of Shareholders - The Malaysian Reserve
Jade Biosciences to Participate in TD Cowen’s 45th Annual - GlobeNewswire
Jade Biosciences, Inc. to Present New Preclinical Data on Jade101 At the 62nd European Renal Association Congress - marketscreener.com
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The MergerIPG, VTS, AVTE, MHLD - The Victoria Advocate
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing - Business Wire
Jade Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
How Fairmount’s Paragon incubator steered two more companies to NASDAQ - BioCentury
Paragon spinout Jade casts reverse merger spell with Aerovate - Fierce Biotech
Paragon launches another company in hot PD-1xVEGF space that goes straight to reverse merger - Endpoints News
Chinook alums reunite following exit to Novartis; The first board appointment for Recursion’s Chris Gibson - Endpoints News
Jade Biosciences Inc Stock (JBIO) Financials Data
There is no financial data for Jade Biosciences Inc (JBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.13%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):